-
-
-
-
-
-
-
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
-
-
-
-
-
-
-
Cingulate reports positive phase 3 trial results for ADHD drug CTx-1301
-
-
-
-
-
-
16,039 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


